---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-24-000104"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:04:18.584647+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share

## Summary
- Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).
- Gross margin 74.7%, down 168 bps YoY due to mix and product costs; operating loss $7.2M vs $4.1M loss.
- Net loss per share $0.17 vs $0.11; adjusted EBITDA $7.8M, down $0.2M vs Q2 2023.
- Generated positive cash flow of $8.1M during the quarter.
- CEO cited strong growth from pain management and AtriClip franchises; advancing LeAAPS trial and new product launches.

## SEC filing metadata
- accession: 0001323885-24-000104
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388524000104/0001323885-24-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388524000104/atrc-20240730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-24-000104
- JSON: https://secwatch.observer/filing/0001323885-24-000104.json
- Plain text: https://secwatch.observer/filing/0001323885-24-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.